3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
4
CNS
4
Other solid neoplasm
1
Genitourinary
1
Gastrointestinal
1
Conditions
Prostatic Neoplasms
11
Carcinoma, Renal Cell
10
Breast Neoplasms
6
Urinary Bladder Neoplasms
5
Melanoma
4
Neoplasm Metastasis
3
Lymphoma
3
Lung Neoplasms
3
Kidney Neoplasms
3
Wilms Tumor
2
Thyroid Neoplasms
2
Stomach Neoplasms
2
Sarcoma, Ewing
2
Sarcoma
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Recurrence
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neuroblastoma
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms
2
Liver Neoplasms
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Hepatocellular
2
Astrocytoma
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
10
X-Rays
7
Specimen Handling
7
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
6
Biopsy
6
ulixertinib
3
palbociclib
3
larotrectinib
3
erdafitinib
3
Temozolomide
3
tipifarnib
2
tazemetostat
2
selpercatinib
2
olaparib
2
ivosidenib
2
ensartinib
2
Vemurafenib
2
Thalidomide
2
Paclitaxel
2
Nivolumab
2
LY3023414
2
Gemcitabine
2
Erlotinib Hydrochloride
2
Cisplatin
2
Carboplatin
2
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
sapanisertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioma
×
Sirolimus
×
Genitourinary
×
Clear all
NCT01331135
2020-05-29
Aflac ST0901
Emory University
Phase 1
Completed
18 enrolled